Login to Your Account



Double Shot Of Bad News Halves Metabasis' Shares

By Trista Morrison


Wednesday, July 18, 2007
Metabasis Therapeutics Inc. lost more than half its value on Tuesday after announcing that CS-917, the lead candidate in its metabolic disease program, failed a Phase IIb diabetes trial, while pradefovir, the lead candidate in its liver disease program, was dropped by partner Schering-Plough Corp. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription